Home » Newsletters » BioWorld Science

BioWorld Science

July 28, 2003

View Archived Issues

Spotlight on viral enzyme inhibitors for the treatment of chronic hepatitis B

Olprinone reduces gut mucosal injury in rabbit model of hypoxia

E-7389 analogues designed to have minimal susceptibility to P-glycoprotein-mediated drug efflux

FR-901228 induces apoptosis in primary and metastatic uveal melanoma cell lines

U. of Minnesota scientists claim new cADPR analogues for use as immunostimulants

AstraZeneca presents new MEK inhibitors in a recent patent

IOP-lowering agents prepared and tested by Alcon researchers

Novel lipase inhibitors for obesity and diabetes in early development at OSI

New NHE-3 inhibitors and their use in sleep apnea, renal failure, stroke, etc.

Taisho patents novel melanocortin MC4 receptor antagonists

Pfizer claims new 5-HT4 receptor modulators and their use in gastrointestinal disorders

Antitumor and antiinflammatory properties of synthetic triterpenoids under study at Dartmouth

Third-generation protease inhibitor active against wild-type and resistant HIV

Lead NPI-2350 (halimide) analogues with improved cytotoxic activity presented at AACR meeting

Preliminary 48-week data from CONTEXT study

CF-101 evaluated in new phase II trial for active RA

Pan-VEGFR tyrosine kinase inhibitor with antiangiogenic and antiproliferative activity

Phase II Canadian trial of MC-4232 cleared to begin

Positive phase II results for arginine deiminase in HCC support initiation of phase III trial

MBI-226 fails to meet primary endpoint in phase III trial

VNP-40101M in combination with AraC tested in new phase I trial for leukemia

La Jolla may seek accelerated approval for Riquent

Zyvox approved for diabetic foot infections

BTG licenses anxiety and depression compounds to Abiogen

FDA clears safinamide IND for Parkinson's disease

Enbrel becomes the first FDA-approved biologic for ankylosing spondylitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...